306 results on '"Buzzoni, Roberto"'
Search Results
2. Diagnosis and management of typical and atypical lung carcinoids
3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
4. Aromatic Oxidation Technologies at Eni/Versalis (Case Study)
5. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
6. A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer
7. Silicalite-1 deactivation in vapour phase Beckmann rearrangement of cyclohexanone oxime to caprolactam
8. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
9. Selective Oxidations at Eni
10. Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab
11. Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
12. Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
13. Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
14. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials
15. Markers of Systemic Inflammation in Neuroendocrine Tumors
16. Reversible bilateral blepharoptosis following oxaliplatin infusion: a case report and literature review
17. Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities
18. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey
19. Sunitinib and everolimus in pancreatic neuroendocrine tumors
20. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience
21. MERKEL CELL CARCINOMA AFTER LIVER TRANSPLANTATION: A CASE REPORT
22. Formestane: an effective first-line endocrine treatment for advanced breast cancer
23. Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer
24. Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women
25. CAPECITABINE IN COMBINATION WITH RADIOTHERAPY IN RECTAL CANCER AFTER CURATIVE SURGERY
26. MEDICAL TREATMENT OF NEUROENDOCRINE TUMORS (NETs) WITH OXALIPLATIN AND CAPECITABINE: AN I.T.M.O. GROUP STUDY
27. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma
28. Medical treatment of advanced and well differentiated neuroendocrine tumours (NETs)
29. Surgical oophorectomy (Ovx) and tamoxifen (T) versus chemotherapy (FEC) and T in premenopausal, node-positive breast cancer
30. Advances in diagnosis and therapy of neuroendocrine tumors
31. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma
32. THE MULTI-TARGETED ANTIFOLATE PEMETREXED DISODIUM (ALIMTA*) WITH FOLIC ACID (FA) SUPPLEMENTATION IN ADVANCED GASTRIC CANCER.
33. ANASTROZOLE IN POST-MENOPAUSAL ADVANCED BREAST CANCER (ABC) PATIENTS: EFFECTS ON STEROIDS AND BONE METABOLISM
34. CAPECITABINE IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER
35. DIFFERENT EFFECT OF EXEMESTANE OR MEGESTROL ACETATE ON INSULIN-LIKE GROWTH FACTOR (IGF) SYSTEM IN METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) HAVING PROGRESSED ON TAMOXIFEN
36. Exemestane in post-menopausal patients failing treatment with non-steroidal structure aromatase inhibitors: Effects on insulin-like growth factor (IGF) components.
37. Anastrozole treatment of post-menopausal breast cancer: Short term effects on insulin-like growth factor (IGF) system.
38. Metastatic melanoma: Chemotherapy
39. Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer
40. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma
41. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian trials in Medical Oncology Group
42. A Phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma
43. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: a study by the Italian Trials in Medical Oncology Group
44. Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial
45. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
46. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge
47. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study
48. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
49. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis
50. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.